4.5 Article

Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis

期刊

CLINICAL GENETICS
卷 74, 期 4, 页码 358-366

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1399-0004.2008.01060.x

关键词

INI1; neurofibromatosis; schwannoma; schwannomatosis; SMARCB1; tumor suppressor gene

资金

  1. NF, Inc
  2. Congressionally Directed Medical Research Fund

向作者/读者索取更多资源

Schwannomatosis is a third major form of neurofibromatosis that has recently been linked to mutations in the SMARCB1 (hSnf5/INI1) tumor suppressor gene. We analyzed the coding region of SMARCB1 by direct sequencing and multiplex ligation-dependent probe amplification (MLPA) in genomic DNA from 19 schwannomatosis kindreds. Microsatellite markers in the SMARCB1 region were developed to determine loss of heterozygosity (LOH) in associated tumors. We detected four alterations in conserved splice acceptor or donor sequences of exons 3, 4 and 6. Two alterations that likely affect splicing were seen in introns 4 and 5. An additional four alterations of unclear pathogenicity were found to segregate on the affected allele in eight families including two non-conservative missense alterations in three families. No constitutional deletions or duplications were detected by MLPA. Nine of 13 tumors examined showed partial LOH of the SMARCB1 region consistent with 'second hits.' Alterations were detected in tumors both with and without somatic NF2 gene changes. These findings support the hypothesis that SMARCB1 is a tumor suppressor for schwannomas in the context of familial disease. Further work is needed to determine its role in other multiple and single tumor syndromes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Extended gene panel testing in lobular breast cancer

Elke M. van Veen, D. Gareth Evans, Elaine F. Harkness, Helen J. Byers, Jamie M. Ellingford, Emma R. Woodward, Naomi L. Bowers, Andrew J. Wallace, Sacha J. Howell, Anthony Howell, Fiona Lalloo, William G. Newman, Miriam J. Smith

Summary: The study found that in women with lobular breast cancer, pathogenic germline variants in genes other than BRCA1/2, such as ATM, also significantly increase the risk of the disease. Extended panel genetic testing can help improve early risk identification and intervention.

FAMILIAL CANCER (2022)

Article Genetics & Heredity

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer

D. Gareth Evans, Elke Maria van Veen, Helen J. Byers, Sarah J. Evans, George J. Burghel, Emma Roisin Woodward, Elaine F. Harkness, Diana M. Eccles, Stephanie L. Greville-Haygate, Jamie M. Ellingford, Naomi L. Bowers, Marta Pereira, Andrew J. Wallace, Sasha J. Howell, Anthony Howell, Fiona Lalloo, William G. Newman, Miriam Jane Smith

Summary: The study shows that the rates of BRCA1, BRCA2, and TP53 PVs are high in very early onset breast cancer cases. Testing of additional breast cancer-associated genes did not provide significant benefits. BRCA1/2 PVs were more common in women aged 26-30 years compared to younger women, and the younger age group had rates similar to other study cohorts.

JOURNAL OF MEDICAL GENETICS (2022)

Article Oncology

PTCH2 is not a strong candidate gene for gorlin syndrome predisposition

Miriam J. Smith, D. Gareth Evans

Summary: Upon evaluating 21 PTCH1/SUFU negative GS families, no pathogenic PTCH2 variants were identified, nor could previously published PTCH2 variants be considered pathogenic based on current guidelines. The absence of clear pathogenic variants in GS families and the high frequency of LoF variants in the general population suggest PTCH2 should not be included in panels for genetic diagnosis of GS.

FAMILIAL CANCER (2022)

Article Genetics & Heredity

Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control study

Nicola Flaum, Elke M. van Veen, Olivia Smith, Stephanie Amico, William G. Newman, Emma J. Crosbie, Richard Edmondson, Miriam J. Smith, D. Gareth Evans

Summary: BRIP1 gene variants are associated with the risk of breast cancer and/or ovarian cancer, with the c.1045G>C variant showing a higher risk, especially for women with EOC. The study underscores the importance of BRIP1 as an EOC susceptibility gene, particularly in familial cases.

CLINICAL GENETICS (2022)

Article Genetics & Heredity

Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis

Rebecca Burns, Kristin Niendorf, Kathleen Steinberg, Amy Mueller, Ina Ly, Justin T. Jordan, Scott R. Plotkin, Stephanie R. Hicks

Summary: This study compared the efficacy of germline-only versus paired genetic testing in clarifying the diagnosis of patients with features of NF2 and SWN. The results showed that paired testing had a higher likelihood of providing diagnostic clarity, especially for patients who had analysis of multiple tumors.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

Article Hematology

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Matthew J. Frigault, Jorg Dietrich, Kathleen Gallagher, Mark Roschewski, Justin T. Jordan, Deborah Forst, Scott R. Plotkin, Daniella Cook, Keagan S. Casey, Kevin A. Lindell, Gabriel D. Depinho, Katelin Katsis, Eva Lynn Elder, Mark B. Leick, Bryan Choi, Nora Horick, Frederic Preffer, Meredith Saylor, Steven McAfee, Paul O'Donnell, Thomas R. Spitzer, Bimalangshu Dey, Zachariah DeFilipp, Areej El-Jawahri, Tracy T. Batchelor, Marcela Maus, Yi-Bin Chen

Summary: This study conducted a clinical trial of tisagenlecleucel in highly refractory patients with primary central nervous system lymphoma (PCNSL). The results showed that most patients responded well to the treatment and there were no severe side effects. This suggests that tisagenlecleucel is safe and effective in this patient population.
Article Genetics & Heredity

Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis

Vanessa L. Merker, Bronwyn Slobogean, Justin T. Jordan, Shannon Langmead, Mark Meterko, Martin P. Charns, A. Rani Elwy, Jaishri O. Blakeley, Scott R. Plotkin

Summary: This study evaluated the extent and reasons for diagnostic delays and errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. The results showed a long median time to diagnosis and a high misdiagnosis rate in patients with schwannomatosis. The study suggests that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve the diagnosis of schwannomatosis.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

Article Genetics & Heredity

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Scott R. Plotkin, Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley, Dusica Babovic-Vuksanovic, Rosalie Ferner, Michael J. Fisher, Jan M. Friedman, Marco Giovannini, David H. Gutmann, Clemens Oliver Hanemann, Michel Kalamarides, Hildegard Kehrer-Sawatzki, Bruce R. Korf, Victor-Felix Mautner, Mia MacCollin, Laura Papi, Katherine A. Rauen, Vincent Riccardi, Elizabeth Schorry, Miriam J. Smith, Anat Stemmer-Rachamimov, David A. Stevenson, Nicole J. Ullrich, David Viskochil, Katharina Wimmer, Kaleb Yohay, Susan M. Huson, Pierre Wolkenstein, D. Gareth Evans

Summary: The study aims to update the diagnostic criteria for neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging. The updated criteria include clinical features and genetic testing, emphasizing the phenotypic overlap between the two conditions.

GENETICS IN MEDICINE (2022)

Article Clinical Neurology

Genome-wide association analysis identifies a susceptibility locus for sporadic vestibular schwannoma at 9p21

Katherine Sadler, John Bowes, Charlie F. Rowlands, Cristina Perez-Becerril, C. Mwee van der Meer, Andrew T. King, Scott A. Rutherford, Omar N. Pathmanaban, Charlotte Hammerbeck-Ward, Simon K. W. Lloyd, Simon R. Freeman, Ricky Williams, Cathal John Hannan, Daniel Lewis, Steve Eyre, D. Gareth Evans, Miriam J. Smith

Summary: A genome-wide association study revealed that rs1556516 in the 9p21.3 region is associated with the risk of vestibular schwannoma. The dysregulation of CDKN2B-AS1 and CDKN2A/B genes in this region has been linked to multiple pathologies, and these genes have been shown to influence each other's expression. The recurrent associations of the 9p21.3 region with known oncogenic pathways provide compelling evidence for its involvement in vestibular schwannoma tumorigenesis.
Article Genetics & Heredity

Differential rates of germline heterozygote and mosaic variants in NF2 may show varying propensity for meiotic or mitotic mutation

D. Gareth Evans, George J. Burghel, Miriam Jane Smith

Summary: NF2-related schwannomatosis is a genetic condition that causes multiple benign tumors of the nervous system. It is caused by pathogenic variants in the NF2 gene, with six specific CpG nonsense variants being responsible for a majority of the cases. The de novo heterozygote to mosaicism ratio of one of these variants, NF2 c.586C>T; p.(Arg196Ter), is higher compared to the others, possibly due to variations in mutation rates during meiosis and mitosis.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers

D. Gareth Evans, Siva Sithambaram, Elke Maria van Veen, George J. Burghel, Helene Schlecht, Elaine F. Harkness, Helen Byers, Jamie M. Ellingford, Ashu Gandhi, Sacha J. Howell, Anthony Howell, Claire Forde, Fiona Lalloo, William G. Newman, Miriam Jane Smith, Emma Roisin Woodward

Summary: This study aimed to investigate the frequency of germline pathogenic variants (PVs) in women with ductal carcinoma in situ (DCIS) and grade 1 invasive breast cancer (G1BC). The results showed that DCIS was more likely to be associated with both BRCA1/2 and non-BRCA1/2 PVs than G1BC. Extended panel testing is recommended for young-onset DCIS where PV detection rates are highest.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161

Miriam J. Smith, Emma R. Woodward, D. Gareth Evans

Summary: Recent genetic sequencing studies have identified loss-of-function variants in the ELP1 and GPR161 genes as causes of childhood medulloblastoma. Although there is speculation that GPR161 may also cause Gorlin syndrome, the projected risks of developing medulloblastoma with these gene variants are relatively low and do not warrant MRI screening in infants.

FAMILIAL CANCER (2023)

Article Oncology

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

Scott R. Plotkin, Jeffrey Allen, Girish Dhall, Jian L. Campian, D. Wade Clapp, Michael J. Fisher, Rakesh K. Jain, James Tonsgard, Nicole J. Ullrich, Coretta Thomas, Lloyd J. Edwards, Bruce Korf, Roger Packer, Matthias A. Karajannis, Jaishri O. Blakeley

Summary: In this prospective multicenter phase II study, the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in persons with NF2-SWN and hearing loss due to VS were evaluated. The results showed that maintenance bevacizumab (5 mg/kg every 3 weeks) was associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.

NEURO-ONCOLOGY (2023)

Article Genetics & Heredity

Validation of lung cancer polygenic risk scores in a high-risk case-control cohort

Mikey B. Lebrett, Miriam J. Smith, Emma J. Crosbie, John Bowes, Helen J. Byers, Gareth Evans, Philip A. J. Crosbie

Summary: The study investigated the performance of previously published polygenic risk scores (PRSs) for lung cancer (LC) and found that genetic variables could be used for screening selection and potentially improve screening effectiveness. Among the 9 PRSs validated in a high-risk case-control cohort, the best-performing PRS had an independent high area under the curve (AUC). Two novel loci, in the DAPK1 and MAGI2 genes, were significantly associated with LC risk. These findings suggest that PRSs may improve LC risk prediction and screening selection.

GENETICS IN MEDICINE (2023)

Article Genetics & Heredity

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

Jineta Banerjee, Jan M. Friedman, Laura J. Klesse, Kaleb H. Yohay, Justin T. Jordan, Scott R. Plotkin, Robert J. Allaway, Jaishri O. Blakeley

Summary: This study investigated whether patients with rare diseases such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) are more susceptible to SARS-CoV-2 infection and severe COVID-19. The results showed that the proportion of positive cases in NF1, NF2, or SWN patients was not significantly higher than in individuals without these rare diseases. There were no severe outcomes reported in the NF2 or SWN cohorts, and the proportion of severe outcomes in NF1 patients was similar to other rare disease cohorts and the general population.

GENETICS IN MEDICINE (2023)

暂无数据